Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01145144|
Recruitment Status : Completed
First Posted : June 16, 2010
Last Update Posted : June 16, 2010
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Stimulation||Drug: dehydroepiandrosterone crystalline fine powder||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
Experimental: DHEA supplementation
DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
Drug: dehydroepiandrosterone crystalline fine powder
|No Intervention: only induction of ovulation by same long protocol without DHEA|
- peak estradiol level.
- number of retrieved oocytes.
- Embryos that were graded as a top quality (according to the number of cells and percent of fragmentation)
- number of embryos reserved for transfer.
- pregnancy rate.
- live birth rate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01145144
|Meir Medical center IVF unit|
|kfar Saba, Israel|
|Meir Medical Center|
|Kfar Sava, Israel|